WinQure Medicine’s Scientific Founder and CSO, Dr. Henrik Ørum, joined leading RNA experts at BioCentury Grand Rounds Europe in Amsterdam for a panel discussion titled “RNA Gets Tenure.”
The session explored what it will take for RNA therapeutics to stand alongside monoclonal antibodies and small molecules as a fully de-risked therapeutic modality.
But recent advances suggest that RNA has already established itself as a mainstream therapeutic approach. The more important question now is how to realize its full potential.
For WinQure Medicine, the opportunity lies in building on the fact that antisense oligonucleotides (ASOs) are already an established platform technology. By applying the same underlying technology, expertise and development infrastructure across multiple ultra-rare disease programs, WinQure is building a commercially viable portfolio model for developing precision therapies for very small patient populations.
Rather than treating each ultra-rare disease program as a standalone development effort, this approach allows capabilities, infrastructure and learnings to be shared across a growing portfolio, reducing development costs and timelines while making therapies commercially viable even for very small patient populations.
The panel brought together Henrik Ørum, Edward Hodgkin (Syncona), Paul Nioi (Alnylam), Martina Roos (Novartis), Sriram Sathyanarayanan (AIRNA) and Leen Thielemans (2 Bridge), moderated by Stephen Hansen (BioCentury).
The discussion reflected an important shift in the field: the question is no longer simply whether RNA therapeutics belong alongside established modalities, but how their potential can be translated into sustainable models that bring therapies to more patients.